Event
Exploring the Future of Biotechnology at ECB2026
Aurelie Dos Santos
Associate – BD & Sales Benelux
European Congress on Biotechnology 2026 ECB
Axxam is pleased to announce its participation in the 20th European Congress on Biotechnology (ECB2026), taking place from 28 June to 1 July 2026 in Antwerp, Belgium. Organized by the European Federation of Biotechnology (EFB) in collaboration with the Flemish Institute for Biotechnology (VIB), ECB2026 brings together scientists, technology innovators, biotechnology companies, and industry leaders to discuss the latest advances shaping the future of biotechnology.
The congress covers a broad range of biotechnology disciplines, spanning healthcare, industrial biotechnology, food and agriculture, sustainability, bioengineering, and emerging technologies, creating opportunities for collaboration between academia and industry.
Meet Axxam at ECB2026
Axxam’s Business Development associate, Aurelie Dos Santos, will attend ECB2026 to connect with biotechnology companies, research institutes, startups, and pharmaceutical organizations interested in accelerating innovation through advanced discovery services.
As a Contract Research Organization (CRO), Axxam supports biotechnology and pharmaceutical partners with integrated solutions spanning target validation, assay development, screening, hit identification, lead optimization support.
Our expertise includes:
- High-throughput screening (HTS)
- High-content screening (HCS)
- Biochemical and cell-based assays
- iPSC-derived disease models and NAMs
- Electrophysiology platforms, including organellar electrophysiology
- GPCR, ion channel, transporter, and enzyme assays
- AI-enabled discovery workflows
- Integrated drug discovery services
How Axxam Supports Biotechnology Innovation
Biotechnology companies often face significant challenges when advancing innovative concepts toward commercial applications. Generating robust biological data, selecting the right experimental models, and efficiently evaluating novel targets are critical steps in the development process.
Axxam helps organizations address these challenges through flexible collaboration models and a broad portfolio of discovery technologies. Whether supporting early-stage research, platform validation, assay development, or advanced screening campaigns, our teams work closely with clients to design solutions tailored to their scientific objectives.
Our integrated approach enables researchers to combine multiple technologies and biological models within a single workflow, helping generate high-quality data and supporting informed decision-making throughout the discovery process.
Let's Connect in Antwerp
If you are attending ECB2026, we would be delighted to meet and discuss your scientific challenges and discovery goals.
Whether you are developing novel therapeutics, building biotechnology platforms, evaluating new biological targets, or seeking a trusted discovery partner, our team looks forward to exploring how Axxam can support your next breakthrough.
Contact us to schedule a meeting with our Business Development Associate during the congress.
About Axxam
Axxam is a Contract Research Organization (CRO) supporting early drug discovery through integrated assay development, screening, compound management, and advanced in vitro platforms.